BR112022016986A2 - Peptídeos cíclicos e seus conjugados para endereçar alfa-v-beta-6-integrina in vivo - Google Patents

Peptídeos cíclicos e seus conjugados para endereçar alfa-v-beta-6-integrina in vivo

Info

Publication number
BR112022016986A2
BR112022016986A2 BR112022016986A BR112022016986A BR112022016986A2 BR 112022016986 A2 BR112022016986 A2 BR 112022016986A2 BR 112022016986 A BR112022016986 A BR 112022016986A BR 112022016986 A BR112022016986 A BR 112022016986A BR 112022016986 A2 BR112022016986 A2 BR 112022016986A2
Authority
BR
Brazil
Prior art keywords
conjugates
integrin
vivo
beta
cyclic peptides
Prior art date
Application number
BR112022016986A
Other languages
English (en)
Portuguese (pt)
Inventor
Notni Johannes
Quigley Neil
Steiger Katja
Original Assignee
Univ Muenchen Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech filed Critical Univ Muenchen Tech
Publication of BR112022016986A2 publication Critical patent/BR112022016986A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
BR112022016986A 2020-03-12 2021-03-12 Peptídeos cíclicos e seus conjugados para endereçar alfa-v-beta-6-integrina in vivo BR112022016986A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20162699 2020-03-12
PCT/EP2021/056424 WO2021180969A1 (en) 2020-03-12 2021-03-12 Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo

Publications (1)

Publication Number Publication Date
BR112022016986A2 true BR112022016986A2 (pt) 2022-10-25

Family

ID=69810651

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016986A BR112022016986A2 (pt) 2020-03-12 2021-03-12 Peptídeos cíclicos e seus conjugados para endereçar alfa-v-beta-6-integrina in vivo

Country Status (11)

Country Link
US (1) US20230173113A1 (https=)
EP (1) EP4117736A1 (https=)
JP (1) JP7787083B2 (https=)
KR (1) KR20220152322A (https=)
CN (1) CN115297893B (https=)
AU (1) AU2021233176A1 (https=)
BR (1) BR112022016986A2 (https=)
CA (1) CA3175061A1 (https=)
IL (1) IL296081A (https=)
MX (1) MX2022011287A (https=)
WO (1) WO2021180969A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226432A2 (en) * 2020-05-08 2021-11-11 The Regents Of The University Of California Methods of detecting and treating lung damage in respiratory-related viral infections
WO2025218677A1 (zh) * 2024-04-16 2025-10-23 中山医诺维申新药研发有限公司 双重靶向成纤维细胞激活蛋白和整合素亚型的化合物及其制备和应用
WO2026027771A1 (en) 2024-08-02 2026-02-05 Trimt Gmbh Alpha v beta 6-integrin binding cyclopeptides with non-natural amino acids, and conjugates thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19933173A1 (de) 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
DK2265283T3 (da) 2008-03-18 2014-10-20 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
CA2937753A1 (en) 2014-02-17 2015-08-20 Seattle Genetics, Inc. Hydrophilic antibody-drug conjugates
SI3350222T1 (sl) 2015-09-18 2022-01-31 Technische Universitaet Muenchen Ligandi za integrin avbeta6, sinteza in uporaba le-teh
EP3468984A4 (en) * 2016-06-13 2020-03-11 The Regents of the University of California ALPHA (V) BETA (6) BINDING PEPTIDES AND METHODS OF USE THEREOF
CA3090196A1 (en) 2018-02-06 2019-08-15 Klinikum Rechts Der Isar Der Technischen Universitat Munchen Compound for intraoperative molecular bioimaging, method of making the same, use thereof in intraoperative molecular bioimaging and surgical method comprising intraoperative molecular bioimaging

Also Published As

Publication number Publication date
KR20220152322A (ko) 2022-11-15
JP2023518161A (ja) 2023-04-28
CA3175061A1 (en) 2021-09-16
MX2022011287A (es) 2022-12-08
CN115297893B (zh) 2025-09-23
JP7787083B2 (ja) 2025-12-16
US20230173113A1 (en) 2023-06-08
WO2021180969A1 (en) 2021-09-16
CN115297893A (zh) 2022-11-04
EP4117736A1 (en) 2023-01-18
IL296081A (en) 2022-11-01
AU2021233176A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
BR112022016986A2 (pt) Peptídeos cíclicos e seus conjugados para endereçar alfa-v-beta-6-integrina in vivo
PH12023550266A1 (en) Anti-ceacam5 antibodies and conjugates and uses thereof
ATE311464T1 (de) Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen
BR112021012222A8 (pt) Molécula de ligação direcionada à célula melhorada
BR112019014615A2 (pt) Receptores de antígeno quimérico contra axl ou ror2 e métodos de uso dos mesmos
WO2017177149A3 (en) Methods and compositions for car t cell therapy
IL262988A (en) Intentional healing
WO2008045976A3 (en) Compositions and methods for treating and diagnosing cancers
BR112013003823A2 (pt) conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
WO2015073746A3 (en) 18f labeling of proteins using sortases
TR201809514T4 (tr) Uzun süre etkili insülin formülasyonları.
HRP20151172T1 (hr) Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
BRPI0810096A2 (pt) Anticorpo anti-epcam e seus usos
GT200900188A (es) Anticuerpos neutralizantes del citomegalovirus humano y su uso.
WO2007121078A3 (en) Catheters with laterally deployable elements and linear ultrasound arrays
TR201815552T4 (tr) Agregasyon ile ilgili hastalıkların tedavisine yönelik iyileştirilmiş nanoantikorlar (TM).
BR112012033295A2 (pt) polipeptídeos curtos e contendo d-aminoácido para conjugados terapêuticos e seu uso
ECSP10010729A (es) Péptidos dirigidos a crkl
DOP2009000208A (es) Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana
ECSP088636A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer
EP4477270A3 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
CY1115212T1 (el) Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44
BR112021025699A2 (pt) Anticorpos anti-mesotelina e imunoconjugados dos mesmos
BR112013003469A2 (pt) agente de formação de imagem, composição de agente de formação de imagem, composição farmacêutica, precursor,e, métodos de preparação do peptídeo cíclico, de preparação da composição, e de formação de imagem do corpo de mamífero in vivo.